Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Temozolomide in Metastatic Ewing's Sarcoma
NCT01313884Phase 2Terminated
- Sponsor
- Stanford University
- Start
- May 2011
- Primary completion
- Jul 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, temozolomide in Ewing sarcoma, sponsored by Stanford University. Started May 2011; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabtemozolomide
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT01313884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313884.